Albert Einstein College of Medicine

University of Pittsburgh

Other

Leland Stanford Junior University

Whitehead Institute for Biomedical Research

Agresearch, New Zealand Pastoral Agriculture Research Institute Ltd.

Harvard College

Duke University

The University of North Carolina at Chapel Hill

Medimmune Limited

Beth Israel Deaconess Medical Center, Inc.

The City University of New York

Plant Bioscience Limited

William R Jacobs, Jr

Barry R Bloom

Betsy C Herold

Graham F Hatfull

Stoyan S Bardarov

Christopher Petro

Ronald W Davis

Richard A Young

Robert N Husson

John S Blanchard

James Sacchettini

Ruth McAdam

Steven A Porcelli

Tsungda Hsu

Vasan Sambandamurthy

Pablo A Gonzalez Munoz

Pablo A Gonzalez-Munoz

David Alland

Ganjam V Kalpana

Mary K Hondalus

Jeffrey D Cirillo

John D McKinney

Sangeeta Tiwari

Martin S Pavelka, Jr

Miriam Braunstein

Geoffrey William De Lisle

Desmond Michael Collins

Svetoslav Bardarov, Legal Representative

Barton F Haynes

Hua-Xin Liao

Charles K Stover

Robert Bittman

Norman L Letvin

John Chan

James M Musser

Mark S Hanson

Samantha Sampson

Rainer Kalscheuer

Stephen Bornemann

Karl Syson

Jeffery S Cox

JoAnn M Tufariello

Volker Briken

Amalio Telenti

Sheldon Morris

Theresa Mary Wilson

Asesh Banerjee

Riku Pamela Kawakami

Lisa Pascopella

Mark Cayabyab

Graham Hatfull

Jae-Sung Yu

Shirley L Haun

Sabine Daugelat

Joseph Dardick

Kari Sweeney

Avi-Hai Hovav

Kayla A Weiss

Dee Dao

Glenn J Fennelly

Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors, compositions and vaccines comprising such, and methods of use thereof are each provided.

HSV-2-delta-gD vaccines and methods for their production and use

Described herein are methods of determining the efficacy of a candidate tuberculosis vaccine and methods of determining the efficacy of a candidate small organic molecule tuberculosis treatment by administering the candidate tuberculosis vaccine or the small organic molecule tuberculosis treatment to an animal which has been infected with an auxotrophic. The auxotrophichas a mycobacterial genome in which (i) argB gene, or a gene encoding a mycobacterial ArgB enzyme, has been fully or partially deleted and (ii) metA gene, or a gene encoding a mycobacterial MetA enzyme, has been fully or partially deleted, wherein theis sterilized in the absence of arginine and methionine). The methods include quantifying the amount of auxotrophicto determine the efficacy.

Double auxotrophic mycobacterium and uses thereof

Provided are attenuated strains ofandBCG which are double auxotrophic mutants with genes knocked out in the biosynthetic pathways for arginine and methionine, and compositions and methods of use thereof.

Double auxotrophicand uses thereof

Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors, virions thereof, compositions and vaccines comprising such, and methods of use thereof are each provided.

Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors

Methods for passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors, virions thereof, compositions and vaccines comprising such.

Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors

Isolated mutantbacteria comprising a deletion in the ESAT-6 gene cluster region 3 (esx-3 region) are provided, as well as compositions comprising such, methods of production thereof and methods of use thereof.

[object Object]

Methods are provided for detecting mycobacteria in a sample, including clinical samples. Methods are also provided for determining susceptibility of mycobacterial strains to known or potential antibiotic agents, as are kits therefor. Recombinant mycobacteriophages are also provided comprising heterologous nucleic acids of interest.

Recombinant mycobacteriophages for delivery of nucleic acids of interest into mycobacteria

Provided are mycobacteria deleted in at least a portion of a region 3 ESAT-6-like gene cluster. Also provided are mycobacteria comprising a mutation in an roc-1 gene. Additionally, vaccines comprising these mycobacteria are provided. Further provided are methods of making a recombinant, methods of inducing an immune response in a mammal, methods of inhibiting IL-12 production in a mammal, and methods of stimulating IL-12 production in a mammal. Vaccine adjuvants are also provided, as are methods of inducing immunity to a target antigen in a mammal.

Mycobacterial mutants inducing IL-12

The present invention provides methods for determining a putative antibacterial, the methods comprising determining whether the putative antibacterial inhibits GlgE or Rv3032. The present invention also provides the antibacterial, the pharmaceutical composition and the method of making the antibacterial as well as a method of treating a subject infected with a bacterial comprising administration of the antibacterial.

Methods for determining chemotherapeutic agents targeting alpha-glucan pathways and uses thereof

Provided are recombinanthaving a mutation in an nlaA gene or in a nuoG gene. Also provided are isolated and purified nlaA proteins and nuoG proteins from a. Additionally provided are isolated and purified nucleic acids comprising a recombinant nlaA gene or a recombinant nuoG gene. Further provided are methods of inducing an immune response in a mammal and methods of making a recombinantusing the nlaA gene or the nuoG gene.

Mycobacterial mutants affecting host apoptosis

Provided are mycobacteria comprising (a) a mutation that is not in a SecA2 gene that attenuates the virulence of the mycobacteria in a mammalian host, and (b) a mutation in a SecA2 gene that eliminates SecA2 activity. Also provided are mycobacteria that comprise a mutation in a SecA2 gene that eliminates SecA2 activity, where the mycobacteria are notor. Additionally provided are methods of inducing an immune response in a mammal and methods of inducing an immune response to a pathogenicin a human using the above mycobacterial mutants.

Mycobacterial SecA2 mutants

Growing community of inventors

City Island, NY, United States of America

William R Jacobs, Jr